“Thepowerful NIH isfunding non
clinicalresearchonminorcannabinoids and severalterpenesincludingmy personal
favourite, beta caryophyllene. Thegoalis to mitigatetheepidemic of
chronicpainthatwillaccompanythe grey tsunami and to decreasetheloss of
productivity and increasedcost ($2000 per person per year)
associatedwithchronicpain.” - Dr. David Hepburn
This
Notice is being provided to allow potential applicants sufficient time to
develop meaningful collaborations and responsive projects, as well as to give
potential applicants sufficient time to determine whether they need to obtain
investigator registration and site licensure from the Drug Enforcement Agency
(DEA) ,if appropriate. For applications that include human use of any of the
compounds, this Notice provides time to determine whether an Investigational
New Drug (IND) application is needed, or if the FDA will provide a written
waiver indicating that an IND is not needed for the proposed research. No
awards will be made to the investigators in the absence of appropriate FDA/IND
documentations for proposed human subject studies.
The FOA
is expected to be published in Winter 2019 with an expected application due
date in March 2019.
Read
full notice here:
0 comments:
Post a Comment